DahariLab

Leeor Hershkovich, Harel Dahari, Scott J. Cotler, Theo Heller, Chris Koh, Jeffrey Glenn, Tarik Asselah, Saeed Hamid, Ohad Etzion. Characterization of HDV RNA and HBsAg during pegylated interferon-alpha and ritonavir-boosted lonafarnib combination therapy: The D-LIVR study. Hepatology 2024 accepted XXXX

Ori Wasserman, Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, Maria Paola Anolli, Sara Colonia Uceda Renteria, Dana Sambarino, Marta Borghi, Riccardo Perbellini, Floriana Facchetti, Ferruccio Ceriotti, Harel Dahari, Pietro Lampertico. Bulevirtide monotherapy in patients with compensated cirrhosis and CSPH: a 96-week interim kinetic analysis of real-life setting. Hepatology 2024 accepted XXXX

Ashish, Goyal, Yuji Ishida, Hiromi Abe-Chayama, Ophir Dahari, Chise Tateno-Mukaidani, Harel Dahari, Kazuaki Chayama. Mathematical modeling of acute HBV infection in humanized mice treated with HBs antibodies. Hepatology 2024 accepted XXXX

​

Mary-Ellen Mackesy-Amiti, Alexander Gutfraind, Eric Tatara, Nicholson T. Collier, Scott J. Cotler, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Bridging the gap between controlled human infection models and real-word testing using computational modeling of randomized hepatitis C vaccine trials. Hepatology 2024 accepted XXXX

Ori Wasserman, Louis Shekhtman, Scott J. Cotler, Elisabetta Degasperi, Maria Paola Anolli, Sara Colonia Uceda Renteria, Dana Sambarino, Marta Borghi, Riccardo Perbellini, Floriana Facchetti, Ferruccio Ceriotti, Harel Dahari, Pietro Lampertico. Bulevirtide monotherapy in patients with compensated cirrhosis and CSPH: a 96-week interim kinetic analysis of real-life setting.

Eric Tatara, Louis Shekhtman, Nicholson Collier, Marian Major, Mary Ellen Mackesy-Amiti, Jonathan Ozik, Basmattee Boodram, Harel Dahari. What happens to HCV incidence after WHO elimination goal is met using direct-acting antivirals? Agent-based modeling emphasizes the need for vaccines to prevent returning to pre-elimination levels in people who inject drugs.

​

Mary-Ellen Mackesy-Amiti, Alexander Gutfraind, Eric Tatara, Nicholson T. Collier, Scott J. Cotler, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Bridging the gap between controlled human infection models and real-word testing using computational modeling of randomized hepatitis C vaccine trials. (Oral talk)

Adquate Mhlanga, E. Fabian Cardozo-Ojeda, Sarah Duehren, Scott J. Cotler, Saeed S. Hamid, Yoav Lurie, Edward Gane, Anat Nevo-Shor, David Yardeni, Jeffrey Glenn, Harel Dahari, Ohad Etzion. Mathematical modeling of HDV RNA, ALT and HBsAg kinetics suggests a dual mode of action of peginterferon lambda: The LIMT-1 Study.

​

Adquate Mhlanga, Rami Zakh, Sarah Duehren, Alexander Churkin, Vladimir Reinharz, Danny Barash, Jeffrey Glenn, Ohad Etzion, Scott J. Cotler, Cihan Yurdaydin, Harel Dahari Understanding the interplay between HDV RNA, HBV DNA and HBsAg during lonafarnib-based therapy via mathematical modeling: The LOWR HDV-1 Study.

​

Zhenzhen Shi, Masataka Tsuge, Takuro Uchida, Yuji Teraoka, Nicholson T. Collier, Susan Uprichard, Jonathan Ozik, Yuji Ishida, Chise Tateno, Harel Dahari, Kazuaki Chayama. Modeling infection kinetics in primary human hepatocytes reveals quantitative insight into HBV production cycle and spread.

​

Louis Shekhtman, Yuji Ishida, Masataka Tsuge, Vladimir Reinharz, Chise Tateno-Mukaidani, Susan L Uprichard, Harel Dahari, Kazuaki Chayama. Modeling of hepatitis B virus kinetics and accumulation of cccDNA in primary human hepatocytes.

Leeor Hershkovich, Harel Dahari, Scott J. Cotler, Ingrid Choong, Colin Hislop, Theo Heller, Chris Koh, Jeffrey Glenn, Tarik Asselah, Saeed Hamid, Ohad Etzion. Characterization of hepatitis D virus RNA and hepatitis B surface antigen kinetics during pegylated interferon-alpha monotherapy: The D-LIVR study. Journal of Hepatology, 2024 Vol 80 (S1): S800-801.

Ashish Goyal, Ohad Etzion, Kimberly Page, Tatyana Kushner, Yedidya Saiman, Scott J Cotler, Harel Dahari. Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration. Journal of Hepatology, 2024 Vol 80 (S1): S832.

​

Eric Tatara, Louis Shekhtman, Nicholson Collier, Marian Major, Jonathan Ozik, Basmattee Boodram, Harel Dahari. What happens to HCV incidence after WHO elimination goal is met? Agent-based modeling predicts sustained availability of direct-acting antivirals among people who inject drugs is required to prevent returning to pre-elimination levels. Journal of Hepatology, 2024 Vol 80 (S1): S43. (Oral Talk)

​

Ashish Goyal, Takuro Uchida, Grace N Makokha, Hiromi Abe-Chayama, Yuji Ishida, Chise Tateno-Mukaidani, Harel Dahari, Kazuaki Chayama. Mathematical modeling of hepatitis B and D viral kinetics during coinfection in humanized mice suggests differences in their infectivity. Journal of Hepatology, 2024 Vol 80 (S1): S735-736.

​

Adquate Mhlanga, Harel Dahari, Leeor Hershkovich, Scott J. Cotler, Ingrid Choong, Colin Hislop, Theo Heller, Chris Koh, Jeffrey Glenn, Tarik Asselah, Saeed Hamid, Ohad Etzion. Modeling dual antiviral activity of lonafarnib to explain hepatitis D virus RNA negativity 24 weeks after end of therapy despite RNA positivity at end of therapy: The D-LIVR study. Journal of Hepatology, 2024 Vol 80 (S1): S814

Adquate Mhlanga, Ohad Etzion, Harel Dahari. A mathematical modeling study on HDV RNA, ALT, and HBsAg dynamics reveals dual mechanisms of peginterferon-lambda​

Mary-Ellen Mackesy-Amiti, Alexander Gutfraind, Eric Tatara, Nicholson T. Collier, Scott J. Cotler, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Bridging the gap between controlled human infection models and real-word testing using computational modeling of randomized hepatitis C vaccine trials. (Oral talk)

Ashish Goyal, Yuji Ishida, Chise Tateno, Andrew Vaillant, Scott J. Cotler, Kazuaki Chayama, Harel Dahari. Mathematical modeling of HBV kinetics in humanized mice suggests that NA blocks not only rcDNA production but also pgRNA synthesis. Hepatology 2023, 78(Suppl. 1): S530-S531.

​

Leeor Hershkovich, Harel Dahari, Scott J. Cotler, Ingrid Choong, Colin Hislop, Ophir Dahari, Theo Heller, Christopher Koh, Jeffrey Glenn, Tarik Asselah, Saeed Hamid, Ohad Etzion. Characterization of HDV RNA kinetic patterns during treatment: The D-LIVR Phase 3 Study. Late-breaking abstract# 5023. Hepatology 2024, 79:E55-56.

​

Sarah Duehren, Takuro Uchida, Masataka Tsuge, Nobuhiko Hiraga, Abu Fahad Abbasi, Ohad Etzion, Jeffrey Glenn; Christopher Koh, Theo Heller, Scott J. Cotler, Kazuaki Chayama, Harel Dahari. Evaluating the Efficacy of Pegylated IFN-λ and IFN-α Treatments on HBV and HDV Infections in Humanized Mice. Hepatology 2023, 78(Suppl. 1): S570.

​

Christina Park, Julian Hercun, Harel Dahari, Ohad Etzion, Saeed S. Hamid, Edward J. Gane, Yoav Lurie, Farial Rahman, David Yardeni, Pallavi Surana, Colin Hislop, Ingrid Choong, Jeffrey Glenn, Theo Heller and Christopher Koh. Understanding the antiviral effects of peginterferon lambda with and without ritonavir boosted lonafarnib in chronic hepatitis D infection. Hepatology 2023, 78(Suppl. 1): S412.

​

E. Fabian Cardozo-Ojeda, Sarah Duehren, Scott J. Cotler, Saeed S. Hamid, Yoav Lurie, Edward Gane, Anat Nevo-Shor, David Yardeni, Ingrid Choong, Jeffrey Glenn, Harel Dahari, Ohad Etzion. Mathematical modeling of HDV RNA, ALT and HBsAg kinetics suggests a dual mode of action of peginterferon lambda: The LIMT-1 Study. Hepatology 2023, 78(Suppl. 1): S579-S580.

​

Adquate Mhlanga, Rami Zakh, Sarah Duehren, Alexander Churkin, Vladimir Reinharz, Danny Barash, Jeffrey Glenn, Ohad Etzion, Scott J. Cotler, Cihan Yurdaydin, Harel Dahari. Understanding the interplay between HDV RNA, HBV DNA and HBsAg during lonafarnib-based therapy via mathematical modeling: The LOWR HDV-1 Study. Hepatology 2023, 78(Suppl. 1): S591-S592.

​

Eric Tatara, Qinyun Lin, Jonathan Ozik, Marynia Kolak, Nicholson Collier, Dylan Halpern, Luc Anselin, Harel Dahari, Basmattee Boodram, John Schneider. Optimizing methadone provider locations for reducing syringe sharing behavior and HCV transmission risk among persons who inject drugs in metropolitan Chicago. Hepatology 2023, 78(Suppl. 1): S698-S699.

​

Eric Tatara, Louis Shekhtman, Nicholson Collier, Basmattee Boodram, Jonathan Ozik, Harel Dahari. Hybrid agent-based and viral kinetics modeling of hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago. Hepatology 2023, 78(Suppl. 1): S688-S689.

​

Ari Josephson, Yuji Ishida, Adquate Mhlanga, Zhenzhen Shi, Chise Tateno-Mukaidani, Jordan J Feld, Harel Dahari, Kazuaki Chayama. Modeling HCV kinetics from inoculation to steady state in SCID humanized mice predicts a partial block of viral production possibly due to an early stage of innate immune response. Hepatology 2023, 78 (Suppl. 1): S749-S750.

Zhenzhen Shi, Adam Burns, Evan Cudone, Karina Durso-Cain, Nicholson Collier, Frederik Graw, Jonathan Ozik, Susan L. Uprichard, Harel Dahari. Modeling cell-to-cell spread of hepatitis C viral infection in vitro using agent-based modelling approach. 

Zhenzhen Shi, Xin Zhang, Niels Cremers, Johan Neyts, Harel Dahari, Suzanne Kaptein. Characterizing of hepatitis E virus infection in a rat model with and without ribavirin interventions.

Eric Tatara, Louis Shekhtman, Nicholson Collier, Jonathan Ozik, Harel Dahari. Hybrid agent-based and viral kinetics modeling of hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.

Ari Josephson, Yuji Ishida, Adquate Mhlanga, Zhenzhen Shi, Chise Tateno-Mukaidani, Jordan J Feld, Harel Dahari, Kazuaki Chayama. Insights into early acute HCV Infection in uPA-SCID Mice with Humanized Livers versus Chimpanzees using Mathematical Modelling Approach. 

Takuro Uchida, Sarah Duehren, Masataka Tsuge, Nobuhiko Hiraga, Susan Uprichard, Ohad Etzion, Jeffrey Glenn; Christopher Koh, Theo Heller, Scott J. Cotler, Kazuaki Chayama, Harel Dahari. Evaluating the Efficacy of Pegylated IFN-λ and IFN-α Treatments on HBV and HDV Infections in Humanized Mice.

Sarah Duehren, Louis Shekhtman, Scott J Cotler, Stephan Aberle, Thomas Reiberger, Peter Ferenci, Harel Dahari. Modeling-based response-guided therapy with bulevirtide monotherapy for chronic hepatitis D to identify patients for finite treatment duration. Journal of Hepatology, 2023 Vol 78 (S1):S1170-1.)

​

Zhenzhen Shi, Xin Zhang, Niels Cremers, Johan Neyts, Harel Dahari, Suzanne Kaptein. Rat hepatitis E virus infection in a rat model has multiphasic viral replication kinetics. Journal of Hepatology, 2023 Vol 78 (S1):S1038-9.

Louis Shekhtman, Scott J Cotler, Elisabetta Degasperi, Maria Paola Anolli, Sara Colonia Uceda Renteria, Dana Sambarino, Marta Borghi, Riccardo Perbellini, Floriana Facchetti, Ferruccio Ceriotti, Pietro Lampertico, Harel Dahari. Modelling HDV kinetics under entry-inhibitor Bulevirtide suggests the existence of two HDV-infected cell populations: implications for response-guided therapy. Hepatology 2023, 77:E144. AASLD 2022 - Late-breaking abstract# 5031

​

Abu Abbasi, Harel Dahari, Nyingi Kemmer, Scott J Cotler, Miguel Malespin. Evaluating Pitfalls Within the Hepatology Training Pipeline. Hepatology 2022, Vol 76 (Suppl. 1): S1071-S1072.

Richard Chiu, Eric R. Tatara, Mary-Ellen Mackesy-Amit, Basmattee Boodram, Jonathan Ozik, Harel Dahari, Alexander Gutfraind. Equitable recruitment to HCV vaccine clinical trials while reducing required sample size in Chicago area. Hepatology 2022, Vol 76 (Suppl. 1): S402-S403.

Zhenzhen Shi, Xin Zhang, Niels Cremers, Johan Neyts, Harel Dahari, Suzanne Kaptein. Rat hepatitis E virus infection in a rat model has multiphasic viral replication kinetics. Journal of Hepatology, 2023 Vol 78 (S1):S1038-9.

Sarah Duehren, Louis Shekhtman, Scott J Cotler, Stephan Aberle, Thomas Reiberger, Peter Ferenci, Harel Dahari. Modeling-based response-guided therapy with bulevirtide monotherapy for chronic hepatitis D to identify patients for finite treatment duration. Journal of Hepatology, 2023 Vol 78 (S1):S1170-1.)

​

S. Maya, L. Hershkovich, E. F. Cardozo-Ojeda, E. Shirvani-Dastgerdi, J. Srinivas, L. Shekhtman, S.L. Uprichard, A. Berneshawi, T.R. Cafiero, H. Dahari, A. Ploss. Mathematical modeling of early hepatitis D virus (HDV) kinetics in transgenic-hNTCP mice reveals biphasic decline post inoculation. 

​

Leeor Hershkovich, Louis Shekhtman, Scott J Cotler, Mathias Jachs, Stephan Aberle, Thomas Reiberger, Peter Ferenci, Harel Dahari. Entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation. 

Adquate Mhlanga, Rami Zakh, Alexander Churkin, Vladimir Reinharz, Harel Dahari, Danny Barash. Towards an improved mathematical model for HDV-HBV interaction.

Zhenzhen Shi, Yuji Ishida, Nicholson T Collier, Michio Imamura, Chise Tateno-Mukaidani, Jonathan Ozik, Jordan J Feld, Harel Dahari, Kazuaki Chayama. Modeling acute HCV infection kinetics in humanized mice.

Louis Shekhtman, Harel Dahari, Scott J. Cotler, Elisabetta Degasperi, Maria Paola Anolli, Sara Colonia Uceda Renteria, Dana, Sambarino, Marta Borghi, Riccardo Perbellini, Floriana Facchetti, Ferruccio Ceriotti, Pietro Lampertico. Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline pattern: an interim kinetic analysis of real-life setting. Journal of Hepatology 2022 vol 77 (S1): S874

​

Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Mark Anderson, Mary Kuhns, Gavin Cloherty, Scott J. Cotler, Andrew Vaillant, Harel Dahari. Characterizing of hepatitis B virus serum RNA kinetics during combination therapy of TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers. Journal of Hepatology 2022 vol 77 (S1): S851-S852

Sarah Duehren, Christopher Koh, Julian Hercun, Farial Rahman, Pallavi Surana, Anusha Vittal, Gil Ben-Yakov, Walter Chunwei Lai, Ohad Etzion, Scott J. Cotler, Jeffrey S. Glenn, Harel Dahari, Theo Heller. Lonafarnib combination with peginterferon Lambda diminished triphasic HDV kinetic pattern seen under Lambda monotherapy: the LIFT HDV Study. (Oral talk). Journal of Hepatology 2022 vol 77 (S1): S70-S71.

E Fabian Cardozo-Ojeda, Sarah Duehren, Saeed S. Hamid, Yoav Lurie, Edward Gane, Nimrah Bader, David Yardeni, Anat Nevo-Shor, Saleh M. Channa, Minaz Mawani, Om Parkash, Ingrid Choong, Scott J. Cotler, Jeffrey Glenn, Harel Dahari, Ohad Etzion. Mathematical modeling of HDV RNA kinetics suggests high peginterferon-lambda efficacy in blocking viral production: Insights from the LIMT-1 study. [PDF] Journal of Hepatology 2022 77 (S1):  vol S859

Ashish Goyal, Alex Churkin, Danny Barash, Scott J Cotler, Amir Shlomai, Ohad Etzion, Harel Dahari. Simplifying mathematical-based response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients. Journal of Hepatology 2022 vol 77 (S1): S588

Zhenzhen Shi, Yuji Ishida, Nicholson T Collier, Michio Imamura, Chise Tateno-Mukaidani, Jonathan Ozik, Jordan J Feld, Harel Dahari, Kazuaki Chayama. Understanding acute HCV infection kinetics in humanized mice via an agent-based modelling approach. Journal of Hepatology 2022 vol 77 (S1): S252.

Duehren S, Cotler SJ, Dahari H, Shi Z, Joyce, C, Fernandez LF, Lee DD. Oxygen saturation during donor warm ischemia time and outcome of donation after circulatory death (DCD) liver transplantation: a review of 1207 cases. https://atcmeetingabstracts.com/abstract/oxygen-saturation-during-donor-warm-ischemia-time-and-outcome-of-donation-after-circulatory-death-dcd-liver-transplantation-a-review-of-1207-cases/. (Oral Talk)

Basmattee boodram, Harel Dahari, Jonathan Ozik, Alexander Gutfraind, Nicholson Collier, Desarae Echevarria, Scott Cotler, Marian Major, Eric Tatara. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago. https://easl.eu/wp-content/uploads/2022/02/Viral-Hepatitis-Elimination-2022-Abstract-book.pdf

Mary-Ellen Mackesy-Amiti, Alexander Gutfraind, Eric Tatara, Nicholson Collier, Scott Cotler, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Simulations of HCV vaccine trials demonstrate effects of background incidence and unbalanced exposure that can impact vaccine efficacy. Hepatology 2021, Vol 74 (1) (Suppl): 604A. (AASLD Presidential Poster of Distinction)

​

Zhenzhen Shi, Masataka Tsuge, Takuro Uchida, Yuji Teraoka, Nicholson T. Collier, Susan Uprichard, Jonathan Ozik, Yuji Ishida, Chise Tateno, Harel Dahari, Kazuaki Chayama. Understanding HBV spread in primary human hepatocytes via an agent-based modelling approach. Hepatology 2021, Vol 74 (1) (Suppl): 537A.

Leeor Hershkovich, Louis Shekhtman, Michel Bazinet, Victor Pântea, Gheorge Placinta, Iurie Moscalu, Scott J. Cotler, Andrew Vaillant, Harel Dahari. Rapid monophasic HBsAg decline during NAP-based therapy predicts functional cure. Hepatology 2021, Vol 74 (1)(Suppl):514A-515A (AASLD Presidential Poster of Distinction)

​

Leeor Hershkovich, Louis Shekhtman, Michel Bazinet,Victor Pântea, Gheorghe Placinta, Iurie Moscalu, Mark Anderson, Jeffrey Gersch, Vera Holzmayer, Mary Kuhns,Gavin A Cloherty, Scott J Cotler, Andrew Vaillant and Harel Dahari. Serum HBV DNA, pregenomic RNA, HBsAg, HBcrAg and ALT kinetic characterization during 24-week tenofovir disoproxil fumarate monotherapy. Hepatology 2021, Vol 74 (1) (Suppl):494A-495A.

Jay Srinivas, Stephanie Maya, Benjamin Y. Winer, Harel Dahari, Alexander Ploss. Mathematical modeling of early hepatitis D virus kinetics in transgenic-hNTCP mice.​ (Oral talk) https://www.fredhutch.org/en/events/workshop-on-virus-dynamics/agenda.html

Stephanie Maya, Jay Srinivas, Elham Shirvani-Dastgerdi, Louis Shekhtman, Susan L. Uprichard, Andrew Berneshawi, Thomas R. Cafiero, Harel Dahari, Alexander Ploss. Mathematical modeling of early hepatitis D virus kinetics in transgenic-hNTCP mice.​

Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Desarae Echevarria, Scott J. Cotler, Marian Major, Basmattee Boodram, Jonathan Ozik, Harel Dahari, Basmattee Boodram. Re-treatment with direct-acting antivirals policy is needed to eliminate Hepatitis C among persons who inject drugs. (Oral Presentation). PLOS ONE 202S. ​https://doi.org/10.1371/journal.pone.0264983

​

Susan L. Uprichard, Karina Durso-Cain, Peter Kumberger, Yannik Schalte, Theresa Fink, Harel Dahari, Jan Hasenauer, Frederik Graw. HCV spread kinetics reveal varying contributions of transmission modes to infection dynamics. 

Leeor Hershkovich, Louis Shekhtman, Michel Bazinet,Victor Pântea, Gheorge Placinta, Iruie Moscalu, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Liviu Iarovoi, Valentina Smesnoi, Tatiana Musteata, Alina Jucov, Scott Cotler, Andrew Vaillant, Harel Dahari. HBsAg, anti-HBs and ALT kinetic characterization during NAP based combination therapy of HBeAg negative chronic hepatitis B infection. Journal Hepatology 2021 vol 72(2): S750-1

​​​

Stephanie Kriss, Alex Churkin, Asher Uziel, Jay Srinivas, Scott Cotler, Ohad Etzion, Amir Shlomai, Danny Barash, Harel Dahari. Real-time utility of response-guided DAA therapy for hepatitis C based on a mathematical modeling approach: database formation and machine learning methods. Journal Hepatology 2021 vol 72(2): S801-2.

Alexander Gutfraind, Mary-Ellen Mackesy-Amiti, Eric Tatara, Nicholson Collier, Scott Cotler, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Simulations of HCV vaccine trials reveal opportunities to re-evaluate vaccine efficacy. Journal Hepatology 2021 vol 72(2): S768.

Jay Srinivas, Stephanie Maya, Benjamin Y. Winer, Harel Dahari, Alexander Ploss. Characterization of serum HBV kinetics from inoculation to steady state in mice engrafted with components of a human immune system (HIS) and/or human hepatocytes (HEP). (Poster of Distinction). Hepatology 2020; Vol. 72, no. 1 (SUPPL): 509A-510A.​

​

Christopher Koh, Julian Hercun, Farial Rahman, Amy Wen-Chun Huang, Ben L. Da, Pallavi Surana, Devika Kapuria, Yaron Rotman, Anusha Vittal, Christy Ann Gilman, Gil Ben-Yakov, Walter Chunwei Lai, Harel Dahari, Jeffrey S. Glenn, and Theo Heller. A Phase 2 Study of Lonafarnib, Ritonavir and Peginterferon Lambda for 24 Weeks: End-of-Study Results from the LIFT HDV Study. (Oral talk, late breaking). Hepatology 2020, accepted.

Jonathan Ozik, Marynia Kolak, Qinyun Lin, Harel Dahari, Basmattee Boodram, John Schneider, Eric Tatara, Nicholson Collier. Measuring social and spatial inequities in access to opioid use disorder treatment for reducing HIV and HCV transmissions. (Publication) Addict Sci Clin Pract 2020, 15(Suppl 2):A37​

Preeti Dubey, Stephanie Maya, Elham Shirvani-Dastgerdi, Hannah Shanes, Susan L. Uprichard, Andrew Berneshawi, Harel Dahari*, Alexander Ploss*. Mathematical modeling of early hepatitis D virus kinetics in transgenic-hNTCP mice. (ePoster oral talk) Journal of Hepatology 2020 vol. 73, S837-838.

​

Christopher Koh, Julian Hercun, Farial Rahman, Amy Wen-Chun Huang, Ben L. Da, Pallavi Surana, Devika Kapuria, Yaron Rotman, Anusha Vittal, Christy Ann Gilman, Gil Ben-Yakov, Walter Chunwei Lai, Harel Dahari, Jeffrey S. Glenn, and Theo Heller. A Phase 2 Study of Lonafarnib, Ritonavir and Peginterferon Lambda for 24 Weeks: End-of-Treatment Results from the LIFT HDV Study. (Late breaking) Journal of Hepatology 2020 vol. 73, S130.

Preeti Dubey, Stephanie Maya, Elham Shirvani-Dastgerdi, Hannah Shanes, Susan L. Uprichard, Andrew Berneshawi, Alexander Ploss*, Harel Dahari*. Modeling early hepatitis D virus kinetics in transgenic-hNTCP mice. (Oral talk)

Basmattee Boodram, Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Jonathan Ozik, Harel Dahari. Towards achieving WHO’s hepatitis C incidence reduction objective by 2030 among persons who inject drugs: Modeling reveals need for retreatment.

Christopher Koh, Ben L. Da, Pallavi Surana, Amy Wen-Chun Huang, Devika Kapuria, Yaron Rotman, Anusha Vittal, Christy Ann Gilman, Gil Ben-Yakov, Walter Chun-wei Lai, Farial Rahman, Julian Hercun, Harel Dahari, Jeffrey S. Glenn, and Theo Heller. A Phase 2 Study of Lonafarnib, Ritonavir and Lambda Interferon for 24 weeks: Interim End-of-Treatment Results from the LIFT HDV Study. Hepatology 2019; accepted (Oral Late breaking).

​

Ohad Etzion, Sarah Duehren, Saeed Sadiq Hamid, Yoav Lurie, Edward Gane, Nimrah Bader, David Yardeni, Anat Nevo-Shor, SM Channa, Minaz Mawani, Om Parkash, Kyunghee Yang, Diane Longo, Susan L. Uprichard; Robert G. Gish, Scott J. Cotler; Jeffrey Glenn, David Apelian, Harel Dahari. Characterization of HDV, HBsAg and ALT kinetics under Peginterferon-Lambda Monotherapy: The Phase 2 LIMT Study. Hepatology 2019; accepted (Late breaking).

​

Swikriti Dasgupta, Michio Imamura, Takashi Nakahara, Masataka Tsuge, Alexander Churkin, David Yardeni, Ohad Etzion, Susan L. Uprichard, Danny Barash, Scott J. Cotler, Harel Dahari*, Kazuaki Chayama*. Modeling-based response-guided therapy under glecaprevir/pibrentasvir may optimize duration of therapy in patients with compensated cirrhosis. Hepatology 2019; Vol 70(Suppl1):931A.

​

Kevin Walsh, Marianne Martinello, Alexander Churkin, Sijia Lou, Tanya Applegate, Ohad Etzion, Susan L. Uprichard, Scott J. Cotler, Danny Barash, Gail Matthews, Harel Dahari. Modeling indicates 100% negative predictive value of achieving cure in subjects with recent HCV infection treated for 6 weeks with sofosbuvir and ribavirin: The DARE II Study. Hepatology 2019; Vol 70(Suppl1):969A-970A.

​

Elham Shirvani-Dastgerdi, Hannah Shanes, Andrew Berneshawi, Harel Dahari*, Alexander Ploss*.HDV RNA decline post inoculation in human NTCP transgenic mice is biphasic. Hepatology 2019; Vol 70(Suppl1):623A-624A. 70th Annual Meeting of the American Association for the study of Liver Diseases. Boston, Ma, USA, Nov 8-12, 2019

​

Preeti Dubey, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Harel Dahari*, Kazuaki Chayama*.  Understanding early HBV kinetics during infection and treatment in primary human hepatocytes: a data-driven mathematical modeling approach. Hepatology 201; Vol 70(Suppl1):178A. (Oral talk)

​

Alexander Gutfraind, Eric Tatara, Nicholson T. Collier, Scott J. Cotler, Stephen Feinstone, Kimberly Page, Jonathan Ozik, Basmattee Boodram, Marian Major, Harel Dahari. Simulation of HCV vaccine clinical trials reveals opportunities and challenges for candidate HCV vaccines. Hepatology 2019; Vol 70 (Suppl1):990A.

Peter Kumberger, Karina Durso-Cain, Yannik Schälte, Theresa Fink, Harel Dahari, Jan Hasenauer, Susan L. Uprichard, Frederik Graw. Hepatitis C virus spread kinetics reveal varying contributions of transmission modes to infection dynamics. Abstract (Oral Talk)

Dahari H*, Etzion O*, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Uprichard SL, Sneh Arbib, Munteanu D, Braun M, Cotler SJ, Abufreha N, Mor O, Shlomai A. Modeling based response guided therapy with DAA shortens treatment duration in HCV treated patients. (Oral Talk)

​

Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Basmattee Boodram, Jonathan Ozik, Harel Dahari. Agent-based modeling of persons who inject drugs in metropolitan Chicago suggests that re-treatment with antivirals of persons who are re-infected with Hep C is critical to achieve the WHO incidence reduction objective by 2030.

Masataka Tsuge, Ken Tsushima, Nobuhiko Hiraga, Takuro Uchida, Michio Imamura, C. Hayes Nelson, Harel Dahari, Susan L. Uprichard, Kazuaki Chayama. Analysis of the association between HBV infection and long term trends in intrahepatic gene expression.

​

Delaina May, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Harel Dahari, Kazuaki Chayama and Susan L Uprichard. HBV infection and spread in HepG2-NTCP cells initiated by low MOI inoculation in the absence of PEG

Alexander Churkin, Vladimir Reinharz, Stephanie Lewkiewicz, Harel Dahari, Danny Barash. HCVMultiscaleFit: A Simulator for Parameter Estimation in Multiscale Models of Hepatitis C Virus Dynamics. (Oral talk)

Danny Barash, Vladimir Reinharz, Alexander Churkin, Harel Dahari. Numerical Methods for Solving and Optimizing Multiscale Models of Hepatitis C Virus Dynamics (Oral talk)

Mini-Symposia titled: “Hepatitis B viral dynamics: mathematical and numerical methods”.

​

Vladimir Reinharz, Danny Barash, and Harel Dahari. PDE modeling simulations and fitting methods for understanding hepatitis B virus infection in humanized mice. (Oral talk)

​

Preeti Dubey, Yuji Ishida, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Kazuaki Chayama* Harel Dahari. Modeling hepatitis B virus infection in primary human hepatocytes. (Oral talk)

Yuji Ishida, Preeti Dubey, Masataka Tsuge, Mikaru Yamao, Chise Tateno, Susan L Uprichard, Harel Dahari*, Kazuaki Chayama*. Characterization of HBV kinetics during infection and treatment in primary human hepatocytes. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e701. https://doi.org/10.1016/S0618-8278(19)31399-4

​

Upendra Kumar, Rafaela VP Ribeiro, Susan L. Uprichard, Marcos Galasso, Atul Humar, Marcelo Cypel, Scott J. Cotler, Harel Dahari*, Jordan J. Feld*. Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e494–e495. https://doi.org/10.1016/S0618-8278(19)30971-5 (oral ePoster)

Louis Shekhtman, Scott J. Cotler, Susan L. Uprichard, Michel Bazinet, Victor Pantea, Valentin Cebotarescu, Lilia Cojuhari, Pavlina Jimbei, Adalbert Krawczyk, Andrew Vaillant, Harel Dahari. Understanding HDV and HBsAg kinetics during nucleic acid polymer REP 2139 mono-therapy in HBeAg-negative chronic HBV/HDV co-infected patients via mathematical modeling. Journal Hepatology 2019; Vol. 70, issue 1. Suppl 1, e463. https://doi.org/10.1016/S0618-8278(19)30913-2

Eric Tatara, Alexander Gutfraind, Nicholson T. Collier, Scott J. Cotler, Marian Major, Basmattee Boodram, Jonathan Ozik, Harel Dahari. Agent-based modeling of persons who inject drugs in metropolitan Chicago suggests that re-treatment with antivirals of persons who are re-infected with Hep C is critical to achieve the WHO incidence reduction objective by 2030

Etzion O*, Dahari H*, Yardeni D, Issachar A, Nevo-Shor A, Cohen-Naftaly M, Uprichard SL, Sneh Arbib O, Munteanu D, Braun M, Cotler SJ, Abufreha N, Mor O, Shlomai A. Response-guided therapy with DAA shortens treatment duration in 50% of HCV treated patients. Hepatology 2018; 68(6); 1468A – 1469A. (Late-Breaking # 34).https://doi.org/10.1002/hep.30353

Karina Durso-Cain, Peter Kumberger, Harel Dahari, Frederik Graw, Susan L. Uprichard.  Dissecting the contribution of cell-to-cell spread to HCV infection dynamics

Upendra Kumar, Takuro Uchida, Kevin Walsh, Michio Imamura, Atesmachew Hailegiorgis, Christopher Koh, Theo Heller, Jeffrey S. Glenn, Susan L. Uprichard, Kazuaki Chayama, Harel Dahari. Preliminary analysis of HBV and HDV dynamics during acute co-infection in uPA/SCID chimeric mice using an agent-based modeling approach. 

Binhui Deng, Sijia Lou, Preeti Dubey, Ohad Etzion, Kazuaki Chayama, Susan L Uprichard, Mark Sulkowski, Scott J Cotler, Harel Dahari. Modeling time to cure after short-duration treatment for chronic HCV with daclatasvir, asunaprevir, beclabuvir and sofosbuvir: The FOURward Study. (Travel award) Journal Viral Hepatitis, 2018, Vol 25 Suppl S2; pg 58. 

https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.45_12923

Sarah Rahman, Kushal Shah, Veronica Loy, Cara Joyce, Harel Dahari, Roshani Naidu, Steve Scaglione and Susan L. Uprichard. Assessing Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C

Preeti Dubey, Christopher Koh, Pallavi Surana, Susan L. Uprichard,  Ma Ai Thanda Han, Nancy Fryzek, Gitanjali Subramanya, Devika Kapuria, Ohad Etzion, Varun Takyar, Yaron Rotman, Cihan Yurdaydin, Jeffrey S. Glenn, Scott J. Cotler, Theo Heller and Harel Dahari. Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV infected patients: A phase 2 LOWR HDV-3 study. Journal Hepatology 2018; Vol. 68, Suppl 1, S508

​

Upendra Kumar, Takuro Uchida, Atesmachew Hailegiorgis, Nobuhiko Hiraga, Kevin Walsh, Michio Imamura, Christopher Koh, Theo Heller, Jeffrey S. Glenn, Susan L. Uprichard, Kazuaki Chayama, Harel Dahari. Understanding HDV and HBV dynamics during acute co-infection in humanized uPA/SCID chimeric mice using an agent-based modeling approach.  Journal Hepatology 2018; Vol. 68, Suppl 1, S783

Atesmachew Hailegiorgis, Yuji Ishida, Michio Imamura, Nobuhiko Hiraga, Hiroshi Yokomichi , Chise Tateno, Susan L. Uprichard, Kazuaki Chayama ,Harel Dahari. Understanding the multiphasic viral kinetics of cute HBV infection observed in humanized uPA/SCID mice using an agent-based modeling approach. Journal Hepatology 2018; Vol. 68, Suppl 1, S782-S783

Louis Shekhtman, Nathaniel Borochov, Scott J. Cotler, Leeor Hershkovich, Susan L. Uprichard, Mamun Al-Mahtab, Michel Bazinet, Andrew Vaillant, Harel Dahari. Modeling serum HBsAg, HBV DNA and transaminase kinetics during REP 2139 monotherapy in chronic HBeAg+ HBV infection. Journal Hepatology 2018; Vol. 68, Suppl 1, S508